Diffuse lung involvement in rheumatoid arthritis:a respiratory physician’s perspective

作     者：Hui Huang Ruxuan Chen Chi Shao Zuojun Xu Paul J.Wolters 

作者机构：Department of Pulmonary and Critical Care MedicinePeking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100730China Department of Pulmonary and Critical Care MedicineUniversity of CaliforniaSan FranciscoCA 94117USA 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第3期

页      面：280-286页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：supported by the National High Level Hospital Clinical Research Funding(No.2022-PUMCHA-009) the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(No.2019XK320037). 

主　　题：Interstitial lung disease Lung Methotrexate pneumonitis Pneumocystis jiroveci pneumonia Rheumatoid arthritis 

摘      要：The lungs are one of the most common extra-articular organs involved in rheumatoid arthritis(RA),which is reported to occur in up to 60%to 80%of RA patients.Respiratory complications are the second leading cause of death due to RA.Although there is a wide spectrum of RA-associated respiratory diseases,interstitial lung disease is the most common manifestation and it impacts the prognosis of RA.There has been progress in understanding the management and progression of rheumatoid arthritis-associated interstitial lung disease(RA-ILD)and RA-associated respiratory diseases recently,for example,opportunistic pulmonary infectious diseases and toxicity from RA therapies.From a chest physicians’perspective,we will update the diagnosis and treatment of RA-associated ILD,methotrexate-associated lung disease,and the complication of Pneumocystis jiroveci pneumonia in RA in this review.